

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary**

May 16, 2012

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Catherine Decker, PharmD	Yes
3	Bradley Fedderly, M.D.	No
4	Lawrence Fleming, M.D.	No
5	Al Liegel, RPh	Yes
6	Kevin Izard, M.D.	Present 12:25 until close of meeting
7	Steve Maike, RPh	Yes
8	Pat Towers	Yes
9	Alicia Walker, PharmD	Present 12:00 until close of meeting
10	Michael Witkovsky, M.D.	Present 11:25 until close of meeting
11	James Boblin, M.D.	Yes
12	Ward Brown, M.D.	No
13	Ronald Diamond, M.D.	No

THERAPEUTIC CLASS REVIEW

HEPATITIS C AGENTS

HIV/AIDS

MULTIPLE SCLEROSIS AGENTS

ANGIOTENSIN MODULATORS

ANGIOTENSIN MODULATOR COMBINATIONS

BETA-BLOCKERS

CALCIUM CHANNEL BLOCKERS

LIPOTROPICS, OTHER

LIPOTROPICS, STATINS

PAH AGENTS, ORAL

ANTICOAGULANTS, INJECTABLE

PLATELET AGGREGATION INHIBITORS

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

HYPOGLYCEMICS, INSULIN

HYPOGLYCEMICS, MEGLITINIDES

HYPOGLYCEMICS, TZD

ANTIEMETICS

PANCREATIC ENZYMES

PROTON PUMP INHIBITORS

ULCERATIVE COLITIS AGENTS

H. PYLORI AGENTS- NEW CLASS

ANTIBIOTICS, GI

ANTIBIOTICS, INHALED

ANTIBIOTICS, VAGINAL

ANTIFUNGALS, ORAL

ANTIVIRALS, ORAL

CEPHALOSPORINS AND RELATED ANTIBIOTICS

FLUOROQUINOLONES, ORAL

MACROLIDES/KETOLIDES

TETRACYCLINES, ORAL

ACNE AGENTS, TOPICAL

ANTIBIOTICS, TOPICAL

ANTIFUNGALS, TOPICAL

ANTIPARASTITICS, TOPICAL

ANTIVIRALS, TOPICAL

ANALGESICS, NARCOTICS LONG

ANALGESICS, NARCOTICS SHORT

ANTIMIGRAINE AGENTS, TRIPTANS

SKELETAL MUSCLE RELAXANTS

BLADDER RELAXANT PREPARATIONS

BONE RESORPTION SUPPRESSION AND RELATED AGENTS

COLONY STIMULATING FACTORS

ERYTHROPOIESIS STIMULATING PROTEINS

GROWTH HORMONE

ADROGENIC AGENTS

BPH TREATMENTS

PHOSPHATE BINDERS

OPIOID DEPENDENCY AGENTS

HEPATITIS C AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PEG-INTRON (SUBCUTANE.)	1.1%	ON	Yes			
RIBAVIRIN TABLET (ORAL)	24.6%	ON	Yes-Generic			
RIBAVIRIN CAPSULE (ORAL)	13.9%	ON	Yes-Generic			
RIBASPHERE 600 MG (ORAL)	0.2%	OFF	No-Generic			
PEG-INTRON REDIPEN (SUBCUTANE.)	10.8%	ON	Yes			
RIBAPAK (ORAL)	2.1%	OFF	No-Generic			
PEGASYS VIAL (SUBCUTANE.)	1.7%	ON	Yes			
RIBASPHERE 400 MG (ORAL)	0.0%	OFF	No-Generic			
PEGASYS SYRINGE (SUB-Q)	8.4%	ON	No	ON	ON	
PEGASYS KIT (SUBCUTANE.)	24.3%	ON	Yes			
PEGASYS PROCLICK (SUB-Q)	0.0%	ON	No	ON	ON	
INFERGEN (SUBCUTANE.)	0.0%	OFF	No			
VICTRELIS (ORAL)	2.9%	ON	Yes			
INCIVEK (ORAL)	10.1%	ON	Yes			

Discussion:

- Kevin Izard stated he supports all Pegasys products being preferred.
- Steve Maike questioned why some Pegasys products are preferred and some are non-preferred.
- Michael Witkovsky made a motion to accept staff recommendations as presented but have all Pegasys products remain preferred.
 - Second- Steve Maike
 - All members were in favor of the motion
 - Motion passes

HIV / AIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NORVIR CAPSULE (ORAL)	3.0%	ON	Yes			
ZIDOVUDINE TABLET (ORAL)	0.5%	ON	Yes-Generic			
NORVIR TABLET (ORAL)	14.1%	ON	Yes			
EPIVIR SOLUTION (ORAL)	0.0%	ON	Yes			
STAVUDINE CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
VIRAMUNE XR (ORAL)	0.4%	ON	Yes			
ZIDOVUDINE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
ZIDOVUDINE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			

HIV / AIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VIRAMUNE SUSPENSION (ORAL)	0.0%	ON	Yes			
VIDEX (ORAL)	0.0%	ON	Yes			
EMTRIVA SOLUTION (ORAL)	0.0%	ON	Yes			
SUSTIVA CAPSULE (ORAL)	0.3%	ON	Yes			
NORVIR SOLUTION (ORAL)	0.0%	ON	Yes			
EPIVIR TABLET (ORAL)	1.3%	ON	Yes			
EMTRIVA CAPSULE (ORAL)	0.5%	ON	Yes			
VIRAMUNE TABLET (ORAL)	1.6%	ON	Yes			
LAMIVUDINE TABLET (ORAL)	0.1%	OFF	No-Generic			
DIDANOSINE (ORAL)	0.3%	ON	No-Generic			
ZIAGEN SOLUTION (ORAL)	0.2%	ON	Yes			
RESCRIPTOR (ORAL)	0.0%	OFF	No			
APTIVUS SOLUTION (ORAL)	0.0%	OFF	No			
ZIAGEN TABLET (ORAL)	1.9%	ON	Yes			
VIREAD (ORAL)	4.2%	ON	Yes			
CRIXIVAN (ORAL)	0.0%	ON	Yes			
SUSTIVA TABLET (ORAL)	1.1%	ON	Yes			
INVIRASE TABLET (ORAL)	0.1%	ON	Yes			
LEXIVA SUSPENSION (ORAL)	0.0%	ON	Yes			
INVIRASE CAPSULE (ORAL)	0.0%	ON	Yes			
KALETRA SOLUTION (ORAL)	0.2%	ON	Yes			
COMBIVIR (ORAL)	1.9%	ON	Yes			
EDURANT (ORAL)	0.0%	ON	Yes			
KALETRA TABLET (ORAL)	4.3%	ON	Yes			
EPZICOM (ORAL)	2.8%	ON	Yes			
INTELENCE (ORAL)	1.2%	OFF	No			
VIRACEPT (ORAL)	0.3%	OFF	No			
TRUVADA (ORAL)	20.2%	ON	Yes			
LAMIVUDINE-ZIDOVUDINE (ORAL)	0.0%	OFF	No-Generic			
LEXIVA TABLET (ORAL)	0.8%	ON	Yes			
REYATAZ (ORAL)	9.3%	ON	Yes			
ISENTRISS (ORAL)	6.6%	ON	Yes			
SELZENTRY (ORAL)	0.3%	OFF	No			
PREZISTA (ORAL)	8.0%	ON	Yes			
APTIVUS CAPSULE (ORAL)	0.0%	OFF	No			
TRIZIVIR (ORAL)	1.2%	ON	Yes			
ATRIPLA (ORAL)	12.1%	ON	Yes			

HIV / AIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
COMPLERA (ORAL)	0.6%	ON	Yes			
FUZEON KIT (INJECTION)	0.0%	OFF	No			

Discussion: None

- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-AI Liegel
 - All members in favor of this motion
 - Motion passes

MULTIPLE SCLEROSIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AVONEX (INTRAMUSC.)	19.3%	ON	Yes			
BETASERON (SUBCUTANE.)	10.6%	ON	Yes			
COPAXONE (SUBCUTANE.)	42.5%	ON	Yes			
REBIF (SUBCUTANE.)	20.4%	ON	Yes			
AMPYRA (ORAL)	5.1%	OFF	No			
EXTAVIA (SUBCUTANE.)	0.0%	OFF	No			
GILENYA (ORAL)	2.1%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second – Kevin Iazard
 - All members were in favor of this motion
 - Motion passes

ANGIOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MICARDIS (ORAL)	0.2%	OFF	No			
CAPTOPRIL (ORAL)	0.7%	ON	Yes-Generic			
BENICAR (ORAL)	0.5%	OFF	No			
LISINOPRIL (ORAL)	44.7%	ON	Yes-Generic			

ANGIOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ENALAPRIL (ORAL)	6.7%	ON	Yes-Generic			
MICARDIS HCT (ORAL)	0.2%	OFF	No			
LISINAPRIL HCTZ (ORAL)	11.4%	ON	Yes-Generic			
BENICAR HCT (ORAL)	0.4%	OFF	No			
BENAZEPRIL (ORAL)	3.7%	ON	Yes-Generic			
RAMIPRIL (ORAL)	0.5%	ON	Yes-Generic			
LOSARTAN (ORAL)	17.1%	ON	Yes-Generic			
ENALAPRIL HCTZ (ORAL)	0.4%	ON	Yes-Generic			
LOSARTAN HCTZ (ORAL)	5.9%	ON	Yes-Generic			
QUINAPRIL (ORAL)	0.5%	ON	Yes-Generic			
MOEXIPRIL (ORAL)	0.0%	OFF	No-Generic			
FOSINOPRIL (ORAL)	0.1%	OFF	No-Generic			
DIOVAN HCT (ORAL)	1.6%	ON	Yes			
DIOVAN (ORAL)	3.4%	ON	Yes			
MOEXIPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
BENAZEPRIL HCTZ (ORAL)	0.7%	ON	Yes-Generic			
EDARBI (ORAL)	0.0%	OFF	No			
EDARBYCLOR (ORAL)	0.0%	OFF	No			
ATACAND (ORAL)	0.2%	OFF	No			
AVAPRO (ORAL)	0.4%	OFF	No			
TEVETEN (ORAL)	0.0%	OFF	No			
TRANDOLAPRIL (ORAL)	0.0%	OFF	No-Generic			
CAPTOPRIL HCTZ (ORAL)	0.0%	ON	Yes-Generic			
ATACAND HCT (ORAL)	0.0%	OFF	No			
TEKTURN HCT (ORAL)	0.0%	OFF	No			
TEKTURN (ORAL)	0.3%	OFF	No			
TEVETEN HCT (ORAL)	0.0%	OFF	No			
AVALIDE (ORAL)	0.1%	OFF	No			
QUINAPRIL HCTZ (ORAL)	0.0%	ON	No-Generic			
PERINDOPRIL (ORAL)	0.0%	OFF	No-Generic			
EPROSARTAN (ORAL)	0.0%	OFF	No-Generic			
FOSINOPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Michael Witkovsky
 - All members were in favor of this motion
 - Motion passes

ANGIOTENSIN MODULATOR COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TARKA (ORAL)	1.7%	ON	Yes			
LOTREL (ORAL)	3.9%	NR	Yes			
EXFORGE (ORAL)	31.5%	ON	Yes			
EXFORGE HCT (ORAL)	6.3%	ON	Yes			
AZOR (ORAL)	34.5%	ON	Yes			
TRIBENZOR (ORAL)	5.8%	ON	Yes			
VALTURNA (ORAL)	9.4%	ON	Yes			
TEKAMLO (ORAL)	0.1%	OFF	No			
AMTURNIDE (ORAL)	0.0%	OFF	No			
AMLODIPINE / BENAZEPRIL (ORAL)	6.9%	OFF	No-Generic			
TWYNSTA (ORAL)	0.0%	OFF	No			

Discussion: None

- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion
 - Motion passes

BETA-BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ATENOLOL (ORAL)	22.5%	ON	Yes-Generic			
TOPROL XL (ORAL)	17.0%	ON	Yes			
PROPRANOLOL / HCTZ (ORAL)	0.0%	ON	Yes-Generic			
METOPROLOL (ORAL)	29.1%	ON	Yes-Generic			
CARVEDILOL (ORAL)	11.0%	ON	Yes-Generic			
BISOPROLOL HCTZ (ORAL)	0.8%	ON	No-Generic			
PROPRANOLOL TABLET (ORAL)	5.3%	ON	Yes-Generic			
ATENOLOL / CHLORTHALIDONE (ORAL)	1.2%	ON	Yes-Generic			

BETA-BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROPRANOLOL SOLUTION (ORAL)	0.3%	ON	Yes-Generic			
DUTOPROL (ORAL)	0.0%	OFF	No			
LEVATOL (ORAL)	0.0%	OFF	No			
SOTALOL (ORAL)	0.7%	ON	Yes-Generic			
NADOLOL (ORAL)	1.2%	ON	Yes-Generic			
LABETALOL (ORAL)	2.8%	ON	Yes-Generic			
ACEBUTOLOL (ORAL)	0.1%	ON	Yes-Generic			
INNOPRAN XL (ORAL)	0.0%	OFF	No			
BYSTOLIC (ORAL)	1.8%	OFF	No			
LOPRESSOR HCT (ORAL)	0.0%	NR	No			
PROPRANOLOL ER (ORAL)	3.0%	ON	Yes-Generic			
PINDOLOL (ORAL)	0.2%	ON	No-Generic			
TIMOLOL (ORAL)	0.1%	ON	No-Generic			
NADOLOL / BENDROFLUMETHIAZIDE (ORAL)	0.0%	ON	No-Generic			
BISOPROLOL (ORAL)	0.6%	ON	No-Generic			
METOPROLOL XL (ORAL)	2.3%	OFF	No-Generic			
METOPROLOL / HCTZ (ORAL)	0.1%	ON	No-Generic			
KERLONE (ORAL)	0.0%	NR	No			
COREG CR (ORAL)	0.1%	OFF	No			
BETAXOLOL (ORAL)	0.0%	OFF	No-Generic			

Discussion:

- Kevin Izard questioned if there are potential savings if members are on separate metoprolol and HCTZ, instead of the combination product.
- Rick Pope stated that dispensing fees come into play as well as compliance with having members take both medications instead of a combination product.
- Michael Witkovsky stated an option could be to prefer pindolol when used with an anti-depressant. Pindolol is used with SSRIs for starting depression therapy for acute suicidality. He suggested keeping pindolol on as preferred when used for this indication. However, the impact would be limited, so obtaining a STAT-PA for the product would be sufficient. Clonidine could also be used for this purpose.
- Rick Pope stated Pindolol is off label use for depression.
- Rachel Currans-Henry stated that DHS could look at Pindolol use with depression (SSRIs) as an action item.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - The vote was 7 to 2 in favor of the motion. Kevin Izard and Alicia Walker were opposed.
 - Motion passes

CALCIUM CHANNEL BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMLODIPINE (ORAL)	67.4%	ON	Yes-Generic			
VERAPAMIL TABLET (ORAL)	1.1%	ON	Yes-Generic			
DILTIAZEM TABLET (ORAL)	1.4%	ON	Yes-Generic			
VERAPAMIL TABLET ER (ORAL)	4.7%	ON	Yes-Generic			
VERAPAMIL CAPSULE (ORAL)	1.3%	ON	Yes-Generic			
DYNACIRC CR (ORAL)	0.1%	ON	No			
CARDENE SR (ORAL)	0.0%	OFF	No			
COVERA-HS (ORAL)	0.0%	OFF	No			
NICARDIPINE (ORAL)	0.1%	ON	Yes-Generic			
DILTIAZEM CAPSULE ER (ORAL)	16.5%	ON	Yes-Generic			
NIFEDIPINE IR (ORAL)	0.2%	ON	Yes-Generic			
ISRADIPINE (ORAL)	0.1%	OFF	No-Generic			
FELODIPINE ER (ORAL)	0.3%	OFF	No-Generic			
NIFEDIPINE ER (ORAL)	6.4%	ON	Yes-Generic			
MATZIM LA (ORAL)	0.0%	OFF	No-Generic			
VERAPAMIL 360 MG CAPSULE (ORAL)	0.2%	ON	No			
VERAPAMIL ER PM (ORAL)	0.0%	OFF	No-Generic			
NISOLDIPINE (ORAL)	0.1%	OFF	No-Generic			
NIMODIPINE (ORAL)	0.0%	ON	Yes-Generic			

Discussion: None

- Alicia Walker made a motion to accept staff recommendations as presented.
 - Second- Rosanne Barber
 - All members were in favor of this motion.
 - Motion passes

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NIACOR (ORAL)	0.0%	ON	Yes-Generic			
ANTARA (ORAL)	0.0%	OFF	No			
GEMFIBROZIL (ORAL)	15.3%	ON	Yes-Generic			
TRIGLIDE (ORAL)	0.0%	OFF	No			
FENOFIBRIC ACID (ORAL)	0.0%	OFF	Yes			

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRILIPIX (ORAL)	5.7%	ON	Yes			
CHOLESTYRAMINE/ASPARTAME (ORAL)	1.8%	ON	Yes-Generic			
NIASPAN (ORAL)	22.3%	ON	Yes			
TRICOR (ORAL)	29.3%	ON	Yes			
COLESTIPOL TABLET (ORAL)	0.6%	OFF	No-Generic			
ZETIA (ORAL)	12.0%	OFF	No			
CHOLESTYRAMINE/SUCROSE (ORAL)	3.5%	ON	Yes-Generic			
FENOFIBRATE TABLET (ORAL)	4.1%	OFF	Yes-Generic			
COLESTIPOL GRANULES (ORAL)	0.0%	OFF	No-Generic			
FENOFIBRATE CAPSULE (ORAL)	2.8%	OFF	No-Generic			
WELCHOL TABLET (ORAL)	1.2%	OFF	No			
LIPOFEN (ORAL)	0.0%	OFF	No			
FIBRICOR (ORAL)	0.0%	OFF	No			
WELCHOL POWDER PACK (ORAL)	0.1%	OFF	No			
LOVAZA (ORAL)	1.1%	OFF	No			

Discussion: None

- Steve Maike made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMVASTATIN (ORAL)	44.3%	ON	Yes-Generic			
LESCOL (ORAL)	0.6%	ON	Yes			
LESCOL XL (ORAL)	0.7%	ON	Yes			
LOVASTATIN (ORAL)	7.9%	ON	Yes-Generic			
PRAVASTATIN (ORAL)	11.2%	ON	Yes-Generic			
CRESTOR (ORAL)	8.6%	ON	No			
VYTORIN (ORAL)	0.5%	OFF	No			
SIMCOR (ORAL)	0.1%	OFF	Yes			

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ADVICOR (ORAL)	0.0%	OFF	No			
ALTOPREV (ORAL)	0.0%	OFF	No			
ATORVASTATIN (ORAL)	6.5%	OFF	Yes-Generic			
LIVALO (ORAL)	0.1%	OFF	No			
LIPITOR (ORAL)	19.5%	ON	No			
CADUET (ORAL)	0.1%	OFF	No			
AMLODIPINE-ATORVASTATIN (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Michael Witkovsky
 - All members were in favor of this motion.
 - Motion passes

PAH AGENTS, ORAL AND INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ADCIRCA (ORAL)	8.5%	ON	Yes			
REVATIO (ORAL)	62.8%	OFF	No			
LETAIRIS (ORAL)	7.6%	ON	Yes			
TRACLEER (ORAL)	19.7%	ON	Yes			
VENTAVIS (INHALATION)	0.4%	ON	Yes		OFF	
TYVASO (INHALATION)	1.1%	OFF	No			

Discussion:

- Catherine Decker questioned if there is a requirement that right heart catheterization or other procedures/clinical criteria are needed before a prostacyclin (inhalation products) Ventavis or Tyvaso can be dispensed? Left heart failure vs. right heart failure is very different, and using the prostacyclin for left heart failure can cause damage.
- Pat Towers stated that utilization numbers appear to show the drugs are being prescribed appropriately.

- Alicia Walker commented that she is concerned about delay in therapy with PA on these products.
- Lynn Radmer stated that there are no specific PA criteria for prostacyclin use.
- Rick Pope stated that utilization on Ventavis and Tyvaso is very small which would likely indicate appropriate prescribing.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - The vote was 6 to 3 in favor of the motion. Catherine Decker, Kevin Izard and Steve Maike were opposed.
 - Motion passes.

ANTICOAGULANTS, INJECTABLE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WARFARIN (ORAL)	90.4%	ON	Yes-Generic			
FRAGMIN DISP SYRIN (SUBCUTANE.)	1.2%	ON	Yes			
PRADAXA (ORAL)	1.7%	OFF	No			
XARELTO (ORAL)	0.0%	OFF	Yes			
LOVENOX SYRINGE (SUBCUTANE.)	5.6%	ON	Yes			
FRAGMIN VIAL (SUBCUTANE.)	0.0%	ON	No			
LOVENOX VIAL (SUBCUTANE.)	0.1%	ON	Yes			
ENOXAPARIN SYRINGE (AUTH GEN) (SUBCUTANE.)	0.0%	OFF	No-Generic			
ENOXAPARIN SYRINGE (SUBCUTANE.)	0.6%	OFF	No-Generic			
ARIXTRA (SUBCUTANE.)	0.2%	ON	No			
FONDAPARINUX (SUBCUTANE.)	0.0%	OFF	No-Generic			

Discussion:

- Alicia Walker indicated that she could see no benefit to adding Xarelto as preferred. She suggested it should be available with a STAT-PA.
- Roseanne Barber made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - The vote was 6 to 3 in favor of the motion. Pat Towers, Alicia Walker and James Boblin opposed.
 - Motion passes

PLATELET AGGREGATION INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TICLOPIDINE (ORAL)	0.2%	OFF	No-Generic			
AGGRENOX (ORAL)	5.3%	ON	Yes			
DIPYRIDAMOLE (ORAL)	0.4%	ON	Yes-Generic			
PLAVIX (ORAL)	93.2%	ON	Yes			
EFFIENT (ORAL)	0.8%	OFF	No			
BRILINTA (ORAL)	0.0%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
KOMBIGLYZE XR (ORAL)	1.5%	ON	Yes			
TRADJENTA (ORAL)	0.1%	OFF	Yes			
JENTADUETO (ORAL)	0.0%	OFF	Yes			
JANUMET (ORAL)	14.9%	ON	Yes			
ONGLYZA (ORAL)	9.7%	ON	Yes			
JANUVIA (ORAL)	69.9%	ON	Yes			
SYMLIN (SUBCUTANE.)	0.0%	OFF	No			
JUVISYNC (ORAL)	0.0%	OFF	No			
BYETTA PENS (SUBCUTANE.)	2.7%	OFF	Yes			
SYMLIN PENS (SUBCUTANE.)	0.5%	OFF	No			
BYDUREON (SUBCUTANE.)	0.0%	NR	No			
VICTOZA (SUBCUTANE.)	0.7%	OFF	No			

Discussion:

- Kevin Izard questioned what is going to be required for the Byetta PA. It will be preferred, but will it require PA? Could the claims system look for a previous script for metformin?
- Alicia Walker questioned how Byetta would be considered as preferred if you still need PA.
- Lynn Radmer stated that current PA policy for Byetta will still be used, based on a step therapy approach using metformin and a sulfonyleurea.
- Lynn Radmer stated Byetta is preferred over Bydureon and Victoza, but still requires PA. Lynn reviewed the PDL Quick Reference with the committee. Lynn explained to the committee that the GLP-1 agents are a sub-category and if the motion passes, Byetta would be preferred in this class over the other two agents, but still require PA.
- Pat Towers stated that Byetta would be available via STAT-PA, but the others would require a paper PA, which is the advantage of Byetta being the preferred agent.

- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - The vote was 8 to 1 in favor of the motion. Kevin Izard opposed.
 - Motion passes

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HUMALOG MIX VIAL (SUBCUTANE.)	1.7%	ON	Yes			
HUMALOG (SUBCUTANE.)	15.2%	ON	Yes			
NOVOLIN VIAL OTC (SUBCUTANE.)	0.1%	OFF	No			
NOVOLOG VIAL (SUBCUTANE.)	0.5%	OFF	No			
NOVOLOG PEN (SUBCUTANE.)	0.5%	OFF	No			
NOVOLOG MIX 70/30 VIAL (SUBCUTANE.)	0.0%	OFF	No			
NOVOLOG MIX 70/30 PEN (SUBCUTANE.)	0.2%	OFF	No			
HUMULIN OTC (SUBCUTANE.)	7.9%	ON	Yes			
NOVOLOG CARTRIDGE (SUBCUTANE.)	0.1%	OFF	No			
HUMULIN 70/30 OTC (SUBCUTANE.)	4.6%	ON	Yes			
HUMALOG MIX PEN (SUBCUTANE.)	2.7%	ON	Yes			
HUMALOG CARTRIDGE (SUBCUTANE.)	1.6%	ON	Yes			
HUMALOG PEN (SUBCUTANE.)	15.9%	ON	Yes			
LANTUS VIAL (SUBCUTANE.)	20.8%	ON	Yes			
LEVEMIR VIAL (SUBCUTANE.)	0.4%	OFF	No			
APIDRA VIAL (SUBCUTANE.)	0.1%	OFF	No			
LEVEMIR PENS (SUBCUTANE.)	0.9%	OFF	No			
APIDRA SOLOSTAR PEN (SUB-Q)	0.1%	OFF	No			
LANTUS SOLOSTAR PEN (SUBCUTANE.)	23.6%	ON	Yes			
LANTUS CARTRIDGE (SUBCUTANE.)	0.0%	ON	Yes			
HUMULIN VIAL (SUBCUTANE.)	0.5%	ON	Yes			
HUMULIN PEN OTC (SUBCUTANE.)	2.6%	ON	Yes			

Discussion: None

- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, MEGLITINIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRANDIN (ORAL)	81.3%	ON	Yes			
NATEGLINIDE (ORAL)	18.7%	OFF	No-Generic			
PRANDIMET (ORAL)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, TZD						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACTOPLUS MET (ORAL)	1.4%	OFF	Yes			
DUETACT (ORAL)	0.1%	OFF	Yes			
AVANDARYL (ORAL)	0.0%	OFF	No			
AVANDIA (ORAL)	0.8%	OFF	No			
ACTOS (ORAL)	97.1%	ON	Yes			
AVANDAMET (ORAL)	0.4%	OFF	No			
ACTOPLUS MET XR (ORAL)	0.2%	OFF	No			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion.
 - Motion passes

ANTIEMETIC/ANTIVERTIGO AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIMENHYDRINATE OTC (ORAL)	0.0%	ON	Yes-Generic			
PROCHLORPERAZINE (ORAL)	7.5%	ON	Yes-Generic			
METOCLOPRAMIDE SOLUTION (ORAL)	0.7%	ON	Yes-Generic			
METOCLOPRAMIDE TABLET (ORAL)	13.1%	ON	Yes-Generic			
PROMETHAZINE SYRUP (ORAL)	1.3%	ON	Yes-Generic			
PROMETHAZINE TABLET (ORAL)	7.8%	ON	Yes-Generic			
ONDANSETRON TABLETS (ORAL)	23.0%	ON	Yes-Generic			
ONDANSETRON ODT (ORAL)	31.9%	ON	Yes-Generic			
MECLIZINE (ORAL)	8.9%	ON	Yes-Generic			
PROMETHAZINE (RECTAL)	1.0%	ON	Yes-Generic			
TRANSDERM-SCOP (TRANSDERM)	2.0%	ON	Yes			
PROCHLORPERAZINE (RECTAL)	0.4%	ON	Yes-Generic			
TRIMETHOBENZAMIDE (ORAL)	0.1%	ON	Yes-Generic			
METOZOLV ODT (ORAL)	0.0%	OFF	No			
MARINOL (ORAL)	0.2%	ON	Yes			
ZUPLLENZ (ORAL)	0.0%	OFF	No			
ONDANSETRON SOLUTION (ORAL)	1.4%	ON	Yes-Generic			
GRANISETRON (ORAL)	0.1%	OFF	No-Generic			
EMEND (ORAL)	0.1%	ON	Yes			
EMEND PACK (ORAL)	0.1%	ON	Yes			
SANCUSO (TRANSDERMAL)	0.1%	OFF	No			
ANZEMET (ORAL)	0.0%	OFF	No			
GRANISOL SOLUTION (ORAL)	0.0%	OFF	No-Generic			
DRONABINOL (ORAL)	0.1%	OFF	No			
CESAMET (ORAL)	0.0%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Rosanne Barber
 - The vote was 8 to 1 in favor of the motion. Catherine Decker opposed.
 - Motion passes

PANCREATIC ENZYMES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANCRELIPASE (ORAL)	12.7%	ON	Yes			
ZENPEP (ORAL)	28.7%	ON	Yes			
CREON (ORAL)	49.2%	OFF	No			
PANCREAZE (ORAL)	9.4%	OFF	No			

Discussion:

- James Boblin questioned the need for continuation of grandfathering on Creon. He does not feel it is necessary.
- Catherine Decker questioned if the grandfathering will stay in place as it is now. The different brands of pancreatic enzymes are not interchangeable at the pharmacy. A script for one cannot be changed to another at the pharmacy, without contacting the provider.
- Kevin Izard stated, if a member has been grandfathered, they should not have to try a different product to remain on the grandfathered drug.
- Alicia Walker stated that we have other drugs that are grandfathered.
- Rachel Currans-Henry stated that mental health drugs are the drugs typically grandfathered.
- Michael Witkovsky stated mental health drugs are different molecules. These enzymes appear to be almost identical, and should be interchangeable.
- Rick Pope stated that the ratio of lipases is very similar between the different products.

- Kevin Izard made a motion to accept staff recommendations as presented and continue current grandfathering policy on Creon.
 - Second- Pat Towers
 - The vote was 6 to 3 in favor of the motion. Al Liegel, Steve Maike and James Boblin opposed.
 - Motion passes

PROTON PUMP INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACIPHEX (ORAL)	13.3%	ON	Yes			
PANTOPRAZOLE (ORAL)	6.4%	ON	Yes-Generic			
PROTONIX SUSPENSION (ORAL)	0.1%	ON	Yes			
OMEPRAZOLE (ORAL)	73.3%	ON	Yes-Generic			
DEXILANT (ORAL)	0.4%	OFF	No			
NEXIUM (ORAL)	3.0%	OFF	No			
NEXIUM SUSPENSION (ORAL)	0.0%	OFF	No			
LANSOPRAZOLE CAPSULES (ORAL)	2.1%	OFF	No-Generic			
PREVACID SOLUTAB (ORAL)	0.6%	OFF	No			
LANSOPRAZOLE SOLUTAB (ORAL)	0.8%	OFF	No-Generic			
PRILOSEC SUSPENSION (ORAL)	0.1%	ON	Yes			

Discussion: None

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Michael Witkovsky
 - All members were in favor of this motion.
 - Motion passes

ULCERATIVE COLITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIPENTUM (ORAL)	0.2%	OFF	No			
SULFASALAZINE (ORAL)	24.2%	ON	Yes-Generic			
SULFASALAZINE DR (ORAL)	5.9%	ON	Yes-Generic			
BALSALAZIDE (ORAL)	4.0%	ON	Yes-Generic			
ASACOL (ORAL)	45.0%	ON	Yes			
APRISO (ORAL)	5.9%	ON	Yes			
PENTASA (ORAL)	6.3%	OFF	No			
LIALDA (ORAL)	3.5%	OFF	No			
CANASA (RECTAL)	3.0%	ON	Yes			
MESALAMINE (RECTAL)	0.3%	OFF	No-Generic			
ASACOL HD (ORAL)	1.8%	OFF	No			
MESALAMINE KIT (RECTAL)	0.1%	OFF	No-Generic			
SFROWASA (RECTAL)	0.0%	OFF	No			

Discussion: None

- Steve Maik made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

PYLORI TREATMENT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HELIDAC (ORAL)	4.6%	NR	Yes			
PYLERA (ORAL)	13.0%	NR	Yes			
PREVPAC (ORAL)	82.4%	NR	No			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

ANTIBIOTICS, GI						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METRONIDAZOLE TABLET (ORAL)	90.6%	ON	Yes-Generic			
NEOMYCIN (ORAL)	0.5%	ON	Yes-Generic			
FLAGYL ER (ORAL)	0.0%	OFF	No			
TINDAMAX (ORAL)	6.2%	ON	No			
ALINIA TABLET (ORAL)	0.1%	ON	Yes			
ALINIA SUSPENSION (ORAL)	0.1%	ON	Yes			
METRONIDAZOLE CAPSULE (ORAL)	0.1%	ON	No-Generic			
VANCOCCIN HCL (ORAL)	1.0%	ON	Yes			
XIFAXAN (ORAL)	1.4%	OFF	No			
DIFICID TABLET (ORAL)	0.0%	OFF	No			

Discussion:

- Lynn Radmer stated that staff if recommending that no PA be required on Tindamax for members 18 years of age and under. The PDL Quick Reference will indicate this exception.
- Kevin Izard questioned if there is any data that shows Tindamax as more effective than a single dose of metronidazole.
- Alicia Walker stated that she sees a lot of use of Tindamax for STDs, and she feels it should be preferred, so members don't have barriers to getting the drug.
- Rick Pope stated that no data suggests that Tindamax is more effective than metronidazole for treatment.
- Al Liegel stated the only difference between using Tindamax vs. metronidazole would be the 2 day vs. 7 day treatment time.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Kevin Izard
 - The vote was 5 to 4 in favor of the motion. Al Liegel, Pat Towers, Alicia Walker and Michael Witkovsky opposed.
 - Motion passes

ANTIBIOTICS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOBI (INHALATION)	91.2%	ON	Yes			
CAYSTON (INHALATION)	8.8%	OFF	No			

Discussion: None

- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion.
 - Motion passes

ANTIBIOTICS, VAGINAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VANDAZOLE (VAGINAL)	5.6%	ON	Yes			
METRONIDAZOLE (VAGINAL)	79.5%	ON	Yes-Generic			
CLEOCIN OVULES (VAGINAL)	3.4%	ON	Yes			
CLINDESSE (VAGINAL)	0.0%	OFF	No			
CLINDAMYCIN (VAGINAL)	11.5%	ON	Yes-Generic			

Discussion: None

- Alicia Walker made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

ANTIFUNGALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUCONAZOLE TABLET (ORAL)	67.2%	ON	Yes-Generic			
TERBINAFINE (ORAL)	3.8%	ON	Yes-Generic			
KETOCONAZOLE (ORAL)	1.4%	ON	Yes-Generic			
NYSTATIN SUSPENSION (ORAL)	17.9%	ON	Yes-Generic			
FLUCONAZOLE SUSPENSION (ORAL)	3.0%	ON	Yes-Generic			
GRIS-PEG (ORAL)	0.9%	ON	Yes			
CLOTRIMAZOLE (MUCOUS MEM)	0.2%	OFF	No-Generic			
NYSTATIN TABLET (ORAL)	0.2%	ON	Yes-Generic			
GRISEOFULVIN SUSPENSION (ORAL)	4.8%	ON	Yes-Generic			
GRIFULVIN V TABLETS (ORAL)	0.0%	OFF	No-Generic			
LAMISIL GRANULES (ORAL)	0.0%	OFF	No			
ITRACONAZOLE (ORAL)	0.2%	ON	Yes			
SPORANOX SOLUTION (ORAL)	0.1%	OFF	No			
VFEND SUSPENSION (ORAL)	0.0%	OFF	No			
ANCOBON (ORAL)	0.0%	OFF	No			
VORICONAZOLE TABLETS (ORAL)	0.2%	OFF	No-Generic			
NOXAFIL (ORAL)	0.0%	OFF	No			
VFEND TABLET (ORAL)	0.0%	OFF	No			
FLUCYTOSINE (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of the motion.
 - Motion passes

ANTIVIRALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACYCLOVIR CAPSULE (ORAL)	3.9%	ON	Yes-Generic			
ACYCLOVIR TABLET (ORAL)	23.4%	ON	Yes-Generic			
AMANTADINE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
AMANTADINE CAPSULE (ORAL)	4.3%	ON	Yes-Generic			
RIMANTADINE (ORAL)	0.0%	ON	Yes-Generic			
AMANTADINE TABLET (ORAL)	0.4%	ON	Yes-Generic			
ACYCLOVIR SUSPENSION (ORAL)	2.4%	ON	Yes-Generic			
TAMIFLU CAPSULE (ORAL)	1.0%	ON	Yes			
RELENZA (INHALATION)	0.1%	ON	Yes			
VALACYCLOVIR (ORAL)	63.8%	ON	Yes-Generic			
FAMCICLOVIR (ORAL)	0.1%	OFF	No-Generic			
TAMIFLU SUSPENSION (ORAL)	0.3%	ON	Yes			

Discussion: None

- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion.
 - Motion passes

CEPHALOSPORINS AND RELATED ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CEPHALEXIN CAPSULE (ORAL)	22.0%	ON	Yes-Generic			
CEFUROXIME TABLET (ORAL)	4.1%	ON	Yes-Generic			
CEFADROXIL CAPSULE (ORAL)	1.6%	ON	Yes-Generic			
AUGMENTIN 125 SUSPENSION (ORAL)	0.0%	ON	Yes			
CEPHALEXIN TABLET (ORAL)	0.0%	ON	Yes-Generic			
SUPRAX TABLET (ORAL)	0.7%	ON	Yes-Generic			
CEPHALEXIN SUSPENSION (ORAL)	5.7%	ON	Yes-Generic			
AMOXICILLIN/CLAV TABLET (ORAL)	23.8%	ON	Yes-Generic			
CEFPROZIL TABLET (ORAL)	1.1%	ON	Yes-Generic			
AMOXICILLIN/CLAV SUSPENSION (ORAL)	17.7%	ON	Yes-Generic			
CEFPROZIL SUSPENSION (ORAL)	2.5%	ON	Yes-Generic			
AUGMENTIN 250 SUSPENSION (ORAL)	0.0%	ON	Yes			
SUPRAX SUSPENSION (ORAL)	0.3%	ON	Yes-Generic			
CEFACLOR CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
CEFDINIR CAPSULE (ORAL)	4.1%	ON	Yes-Generic			
CEDAX CAPSULE (ORAL)	0.0%	OFF	No			
AMOXICILLIN/CLAV CHEW TABLET (ORAL)	0.5%	ON	Yes-Generic			
CEFADROXIL TABLET (ORAL)	0.0%	ON	Yes-Generic			
CEFDINIR SUSPENSION (ORAL)	14.7%	ON	Yes-Generic			
CEFADROXIL SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
CEFTIN SUSPENSION (ORAL)	0.5%	ON	Yes			
CEFPODOXIME SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
CEDAX SUSPENSION (ORAL)	0.0%	OFF	Yes			
AMOXICILLIN/CLAV XR (ORAL)	0.0%	OFF	No-Generic			
SPECTRACEF (ORAL)	0.0%	OFF	No			
CEFPODOXIME TABLET (ORAL)	0.0%	OFF	No-Generic			
CEFACLOR TABLET ER (ORAL)	0.0%	ON	No-Generic			
CEFDITOREN (ORAL)	0.0%	OFF	No			

Discussion: None

- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - The vote was 8 to 1 in favor of the motion. Alicia Walker opposes.
 - Motion passes

FLUOROQUINOLONES, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CIPROFLOXACIN TABLET (ORAL)	69.2%	ON	Yes-Generic			
LEVOFLOXACIN TABLET (ORAL)	30.1%	ON	Yes-Generic			
CIPROFLOXACIN ER (ORAL)	0.0%	OFF	No-Generic			
AVELOX (ORAL)	0.4%	OFF	No			
OFLOXACIN (ORAL)	0.0%	OFF	No-Generic			
NOROXIN (ORAL)	0.0%	OFF	No			
FACTIVE (ORAL)	0.0%	OFF	No			
CIPRO SUSPENSION (ORAL)	0.2%	OFF	No			
LEVAQUIN SOLUTION (ORAL)	0.0%	OFF	No			
LEVOFLOXACIN SOLUTION (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

MACROLIDES/KETOLIDESS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ERYTHROMYCIN BASE CAPSULE DR (ORAL)	0.0%	ON	Yes-Generic			
AZITHROMYCIN TABLET (ORAL)	61.7%	ON	Yes-Generic			
AZITHROMYCIN PACKET (ORAL)	0.3%	ON	Yes			
CLARITHROMYCIN TABLET (ORAL)	1.5%	ON	Yes-Generic			
AZITHROMYCIN SUSPENSION (ORAL)	35.1%	ON	Yes-Generic			
ZMAX (ORAL)	0.0%	OFF	No			
ERYTHROMYCIN BASE TABLET (ORAL)	0.6%	ON	Yes-Generic			
ERYTHROMYCIN (ORAL)	0.0%	ON	Yes-Generic			
ERYTHROCIN (ORAL)	0.1%	ON	Yes-Generic			
E.E.S. 400 TABLET (ORAL)	0.2%	ON	Yes-Generic			
CLARITHROMYCIN SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	No-Generic			
KETEK (ORAL)	0.0%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion.
 - Motion passes

TETRACYCLINES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOXYCYCLINE HYCLATE TABLET (ORAL)	30.5%	ON	Yes-Generic			
DOXYCYCLINE HYCLATE CAPSULE (ORAL)	42.2%	ON	Yes-Generic			
TETRACYCLINE (ORAL)	6.1%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
ORACEA (ORAL)	0.0%	OFF	No			
VIBRAMYCIN SUSPENSION (ORAL)	0.0%	OFF	No			
MINOCYCLINE CAPSULES (ORAL)	20.6%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE TABLET (ORAL)	0.0%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE BRAND (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE BRAND (ORAL)	0.0%	OFF	No			
VIBRAMYCIN SYRUP (ORAL)	0.1%	OFF	No			
MINOCYCLINE ER (ORAL)	0.0%	OFF	No-Generic			
DEMECLOCYCLINE (ORAL)	0.3%	OFF	No-Generic			
DOXYCYCLINE HYCLATE TABLET DR (ORAL)	0.0%	OFF	No-Generic			
DORYX (ORAL)	0.1%	OFF	No			
MINOCYCLINE TABLETS (ORAL)	0.0%	OFF	No-Generic			
MORGIDOX KIT (MISCELL)	0.0%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 75 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 150 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Michael Witkovsky
 - All members were in favor of this motion.
 - Motion passes

ACNE AGENTS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZELEX (TOPICAL)	1.7%	ON	Yes			
CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)	7.3%	ON	Yes-Generic			
DIFFERIN CREAM (TOPICAL)	2.8%	ON	Yes			
TAZORAC CREAM (TOPICAL)	0.4%	OFF	No			
ERYTHROMYCIN GEL (TOPICAL)	3.0%	ON	Yes-Generic			
DIFFERIN LOTION (TOPICAL)	0.2%	ON	Yes			
BENZOYL PEROXIDE GEL (TOPICAL)	15.2%	ON	Yes-Generic			
TAZORAC GEL (TOPICAL)	0.2%	OFF	No			
DESQUAM-X (TOPICAL)	0.0%	ON	Yes-Generic			
ERYTHROMYCIN SOLUTION (TOPICAL)	0.7%	ON	Yes-Generic			
AKNE-MYCIN (TOPICAL)	0.0%	OFF	No			
RETIN-A MICRO (TOPICAL)	7.5%	ON	Yes			
DIFFERIN GEL (TOPICAL)	5.8%	ON	Yes			
CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)	10.7%	ON	Yes-Generic			
CLINDAMYCIN PHOSPHATE GEL (TOPICAL)	20.6%	ON	Yes-Generic			
SULFACETAMIDE / SULFUR CLEANSER BRAND (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE CLEANSER (TOPICAL)	1.1%	ON	Yes-Generic			
SULFACETAMIDE / SULFUR LOTION (TOPICAL)	0.2%	OFF	No-Generic			
CERISA (TOPICAL)	0.0%	OFF	No-Generic			
BENZOYL PEROXIDE LOTION (TOPICAL)	0.0%	ON	Yes-Generic			
BENZAACLIN (TOPICAL)	0.1%	OFF	No			
ATRALIN (TOPICAL)	0.0%	OFF	No			
CLINDAGEL (TOPICAL)	0.0%	OFF	No			
TRETINOIN GEL (TOPICAL)	4.8%	ON	Yes-Generic			
TRETINOIN CREAM (TOPICAL)	14.4%	ON	Yes-Generic			

ACNE AGENTS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SULFACETAMIDE / SULFUR SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.1%	OFF	No			
NUOX (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE SUSPENSION (TOPICAL)	0.1%	OFF	No-Generic			
ACZONE (TOPICAL)	0.3%	OFF	No			
BENZAMYCIN (TOPICAL)	0.0%	OFF	No			
SEB-PREV (TOPICAL)	0.0%	OFF	No			
10-1 (TOPICAL)	0.0%	OFF	No-Generic			
GARIMIDE (TOPICAL)	0.0%	OFF	No-Generic			
EPIDUO (TOPICAL)	0.2%	OFF	No			
ZIANA (TOPICAL)	0.1%	OFF	No			
CLENIA (TOPICAL)	0.0%	OFF	No-Generic			
CLARIFOAM EF (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE / SULFUR CLEANSER (TOPICAL)	1.4%	OFF	No-Generic			
CLINDAMYCIN / BENZOYL PEROXIDE (TOPICAL)	0.5%	OFF	No-Generic			
AVAR CLEANSER (TOPICAL)	0.0%	OFF	No			
PACNEX (TOPICAL)	0.0%	OFF	No-Generic			
ADAPALENE GEL (TOPICAL)	0.3%	OFF	No-Generic			
ADAPALENE CREAM (TOPICAL)	0.2%	OFF	No-Generic			
SSS 10-4 (TOPICAL)	0.0%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE FOAM (TOPICAL)	0.2%	ON	No-Generic			
VELTIN (TOPICAL)	0.0%	OFF	No			
SULFACETAMIDE CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			

Discussion: None

- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion.
 - Motion passes

ANTIBIOTICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRIPLE ANTIBIOTIC OINTMENT OTC (TOPICAL)	15.3%	ON	Yes-Generic			
BACITRACIN OTC (TOPICAL)	10.3%	ON	Yes-Generic			
GENTAMICIN OINTMENT (TOPICAL)	1.0%	ON	Yes-Generic			
NEOMYCIN / POLYMYXIN / PRAMOXINE	0.0%	ON	Yes-Generic			
BACITRACIN/POLY,XYLIN OTC (TOPICAL)	1.6%	ON	Yes-Generic			
GENTAMICIN CREAM (TOPICAL)	0.9%	ON	Yes-Generic			
TRIPLE ANTIBIOTIC PLUS OINT. OTC (TOPICAL)	0.0%	ON	Yes-Generic			
MUPIROCIN OINTMENT (TOPICAL)	70.7%	ON	Yes-Generic			
BACTROBAN CREAM (TOPICAL)	0.0%	OFF	No			
GENTANY (TOPICAL)	0.0%	OFF	No			
ALTABAX (TOPICAL)	0.0%	OFF	No			

Discussion: None

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - All members were in favor of this motion.
 - Motion passes

ANTIFUNGALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)	1.5%	ON	Yes-Generic			
TOLNAFTATE CREAM OTC (TOPICAL)	0.2%	ON	Yes-Generic			
TOLNAFTATE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)	4.9%	ON	Yes-Generic			
NYSTATIN CREAM (TOPICAL)	20.4%	ON	Yes-Generic			
NYSTATIN OINT (TOPICAL)	8.4%	ON	Yes-Generic			
TINACTIN CREAM OTC (TOPICAL)	0.0%	ON	Yes			

ANTIFUNGALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOTRIMAZOLE SOLUTION OTC (TOPICAL)	0.1%	ON	Yes-Generic			
MICONAZOLE CREAM OTC (TOPICAL)	2.8%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM OTC (TOPICAL)	7.0%	ON	Yes-Generic			
MICONAZOLE OINT OTC (TOPICAL)	0.0%	ON	Yes-Generic			
LOTTRIMIN AF CREAM OTC (TOPICAL)	0.0%	ON	Yes-Generic			
MENTAX (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SOLUTION (TOPICAL)	0.2%	OFF	No-Generic			
CLOTRIMAZOLE SOLUTION RX (TOPICAL)	0.6%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM RX (TOPICAL)	13.8%	ON	Yes-Generic			
OXISTAT CREAM (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE SHAMPOO (TOPICAL)	10.2%	ON	Yes-Generic			
KETOCONAZOLE CREAM (TOPICAL)	8.8%	ON	Yes-Generic			
NYSTATIN POWDER (TOPICAL)	8.8%	ON	Yes-Generic			
CICLOPIROX CREAM (TOPICAL)	0.1%	OFF	No-Generic			
ECONAZOLE (TOPICAL)	0.2%	OFF	No-Generic			
EXELDERM SOLUTION (TOPICAL)	0.0%	OFF	No			
OXISTAT LOTION (TOPICAL)	0.0%	OFF	No			
NAFTIN CREAM (TOPICAL)	0.1%	OFF	No			
EXELDERM CREAM (TOPICAL)	0.0%	OFF	No			
CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)	11.3%	ON	Yes-Generic			
CICLOPIROX SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
ERTACZO (TOPICAL)	0.0%	OFF	No			
CLOTRIMAZOLE-BETAMETHASONE LOTION (TOPICAL)	0.5%	ON	Yes-Generic			
VUSION (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
CICLOPIROX GEL (TOPICAL)	0.0%	OFF	No-Generic			
BENSAL HP (TOPICAL)	0.0%	OFF	No			
NAFTIN GEL (TOPICAL)	0.0%	OFF	No			
EXTINA (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE FOAM (TOPICAL)	0.0%	OFF	No-Generic			

Discussion: None

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

ANTIPARASITICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PERMETHRIN OTC (TOPICAL)	26.0%	ON	Yes-Generic			
EURAX CREAM (TOPICAL)	0.1%	OFF	Yes			
ULESFIA (TOPICAL)	0.6%	OFF	No			
OVIDE (TOPICAL)	2.5%	NR	Yes			
PERMETHRIN (TOPICAL)	69.0%	ON	Yes-Generic			
NATROBA (TOPICAL)	0.1%	OFF	No			
LINDANE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
MALATHION BRAND (TOPICAL)	1.4%	OFF	No			
LINDANE SHAMPOO (TOPICAL)	0.2%	OFF	No-Generic			
EURAX LOTION (TOPICAL)	0.0%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

ANTIVIRALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOVIRAX OINTMENT (TOPICAL)	70.9%	ON	Yes			
DENAVIR (TOPICAL)	27.6%	ON	Yes			
ZOVIRAX CREAM (TOPICAL)	1.5%	OFF	No			
XERESE (TOPICAL)	0.0%	OFF	No			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

ANALGESICS, NARCOTICS LONG						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RYZOLT (ORAL)	0.0%	OFF	No			
METHADONE SOUTION (ORAL)	0.2%	ON	Yes-Generic			
METHADONE TABLET (ORAL)	18.4%	ON	Yes-Generic			
METHADONE CONC (ORAL)	6.0%	ON	Yes-Generic			
METHADONE SOL TABLET (ORAL)	0.0%	ON	Yes-Generic			
METHADONE BRAND SOL TABLET (ORAL)	0.0%	ON	Yes			
MORPHINE ER (ORAL)	33.1%	ON	Yes-Generic			
KADIAN (ORAL)	2.7%	ON	No			
CONZIP (ORAL)	0.0%	OFF	No			
FENTANYL (TRANSDERM)	22.5%	ON	Yes-Generic			
BUTRANS (TRANSDERM)	0.5%	OFF	Yes			
TRAMADOL ER (ORAL)	0.3%	OFF	No-Generic			
MORPHINE ER (KADIAN AUTH GEN) (ORAL)	0.0%	OFF	No-Generic			
ULTRAM ER 300mg (ORAL)	0.0%	OFF	No			
TRAMADOL ER (GENERIC RYZOLT ER) (ORAL)	0.0%	OFF	No-Generic			
NUCYNTA ER (ORAL)	0.1%	OFF	No			
OXYMORPHONE ER (ORAL)	0.0%	OFF	No-Generic			
AVINZA (ORAL)	0.1%	OFF	No			
OPANA ER (ORAL)	1.0%	OFF	No			
OXYCONTIN (ORAL)	14.8%	OFF	No			
EXALGO (ORAL)	0.1%	OFF	No			
MORPHINE ER (KADIAN GENERIC) (ORAL)	0.0%	OFF	No-Generic			

Discussion:

- Catherine Decker asked if there is a generic Kadian that is preferred. Kadian is dosed once daily and morphine ER is dosed every 12 hours.
- Kevin Izard asked what the difference is between Kadian and morphine ER. There are not many options besides morphine that are preferred. He would like to see two preferred long acting options.
- Steve Maiké stated when Kadian was preferred; it did not have much market share.
- Rick Pope stated that the generic Kadian is not currently preferred.
- Lynn Radmer stated that generic Kadian would remain non-preferred but there are other preferred products available.
- Rick Pope stated that when products are dosed at equal morphine equivalents, they are all equally effective for pain management treatment.

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - The vote was 8 to 1 in favor of the motion. Alicia Walker opposes.
 - Motion passes

ANALGESICS, NARCOTICS SHORT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
APAP / CODEINE ELIXIR (ORAL)	0.9%	ON	Yes-Generic			
TRAMADOL (ORAL)	14.1%	ON	Yes-Generic			
MEPERIDINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
HYDROCODONE / APAP TABLET (ORAL)	46.0%	ON	Yes-Generic			
APAP / CODEINE TABLET (ORAL)	6.8%	ON	Yes-Generic			
COCET (ORAL)	0.0%	ON	No-Generic			
HYDROCODONE / APAP SOLUTION (ORAL)	0.8%	ON	Yes-Generic			
OXYCODONE / APAP CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
HYDROCODONE / APAP CAPSULE (ORAL)	0.0%	ON	Yes-Generic			
ROXICODONE TABLET (ORAL)	0.0%	ON	Yes			
MORPHINE SOLUTION (ORAL)	0.1%	ON	Yes			
COCET PLUS (ORAL)	0.0%	OFF	No-Generic			
MEPERIDINE TABLET (ORAL)	0.0%	OFF	No-Generic			
HYDROMORPHONE TABLET (ORAL)	0.6%	ON	Yes-Generic			
OXYCODONE / APAP TABLET (ORAL)	17.2%	ON	Yes-Generic			
ROXICET SOLUTION (ORAL)	0.5%	ON	Yes-Generic			
OXYCODONE CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
HYDROCODONE / IBUPROFEN (ORAL)	0.4%	ON	Yes-Generic			
MORPHINE IR TABLET (ORAL)	0.6%	ON	Yes			
IBUDONE (ORAL)	0.0%	OFF	No-Generic			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Generic			
ZOLVIT (ORAL)	0.0%	OFF	No-Generic			
ROXICET 5-500 CAPLET (ORAL)	0.0%	ON	Yes			
TREXIX (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.1%	OFF	No-Generic			
ZYDONE (ORAL)	0.0%	ON	Yes-Generic			
BUTORPHANOL TARTRATE (NASAL)	0.0%	ON	Yes-Generic			
OXYCODONE TABLET (ORAL)	11.0%	ON	Yes-Generic			
CODEINE (ORAL)	0.1%	ON	Yes-Generic			
OXYCODONE / ASA BRAND (ORAL)	0.0%	OFF	No			
HYCET (ORAL)	0.0%	NR	No-Generic			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	OFF	No-Generic			

ANALGESICS, NARCOTICS SHORT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MORPHINE CONC SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
MORPHINE SUPPOSITORIES (RECTAL)	0.0%	ON	Yes-Generic			
PENTAZOCINE / APAP (ORAL)	0.0%	OFF	No-Generic			
LEVORPHANOL (ORAL)	0.0%	OFF	No-Generic			
REPREXAIN (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE / ASA (ORAL)	0.0%	OFF	No-Generic			
ZAMICET (ORAL)	0.0%	OFF	No-Generic			
HYDROMORPHONE SUPPOSITORIES (RECTAL)	0.0%	ON	No-Generic			
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Generic			
XOLOX (ORAL)	0.0%	NR	No-Generic			
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	0.0%	OFF	No-Generic			
DILAUDID LIQUID (ORAL)	0.0%	OFF	No			
CARISOPRODOL COMPOUND-CODEINE (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE CONC (ORAL)	0.0%	ON	No-Generic			
XODOL (ORAL)	0.0%	NR	No			
RYBIX ODT (ORAL)	0.0%	OFF	No			
MAGNACET (ORAL)	0.0%	NR	No-Generic			
OXECTA (ORAL)	0.0%	OFF	No			
CAPITAL W-CODEINE (ORAL)	0.0%	ON	Yes-Generic			
NUCYNTA (ORAL)	0.1%	OFF	No			
OXYMORPHONE (ORAL)	0.0%	OFF	No-Generic			
PRIMALEV (ORAL)	0.0%	NR	No-Generic			
ONSOLIS (BUCCAL)	0.0%	OFF	No			
FENTANYL (BUCCAL)	0.0%	OFF	No-Generic			
FENTORA (BUCCAL)	0.0%	OFF	No			
ABSTRAL (SUBLINGUAL)	0.0%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion.
 - Motion passes

ANTIMIGRAINE AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SUMATRIPTAN (ORAL)	70.1%	ON	Yes-Generic			
IMITREX VIAL (SUBCUTANE.)	0.0%	NR	Yes			
IMITREX KIT (SUBCUTANE.)	0.0%	NR	Yes			
RELPAK (ORAL)	2.6%	OFF	Yes			
MAXALT MLT (ORAL)	1.9%	OFF	No			
FROVA (ORAL)	0.5%	OFF	No			
MAXALT TABLET (ORAL)	4.3%	OFF	No			
NARATRIPTAN (ORAL)	8.9%	ON	Yes-Generic			
IMITREX (NASAL)	0.1%	NR	Yes			
AXERT (ORAL)	0.2%	OFF	No			
ZOMIG (ORAL)	0.8%	OFF	No			
ZOMIG ZMT (ORAL)	0.2%	OFF	No			
ZOMIG (NASAL)	0.1%	OFF	No			
SUMATRIPTAN VIAL (SUBCUTANE.)	0.1%	ON	No-Generic			
TREXIMET (ORAL)	0.3%	OFF	No			
IMITREX (ORAL)	0.1%	NR	No			
SUMATRIPTAN PEN INJCTR (SUBCUTANE.)	1.6%	ON	No-Generic			
SUMATRIPTAN (NASAL)	2.8%	ON	No			
CAMBIA (ORAL)	0.0%	OFF	No			
SUMATRIPTAN KIT (SUBCUTANE.)	5.3%	ON	No			
SUMATRIPTAN DISP SYRIN (SUBCUTANE.)	0.0%	ON	No-Generic			
SUMAVEL DOSEPRO (SUBCUTANE.)	0.0%	OFF	No			

Discussion:

- Catherine Decker stated that migraines occur very quickly. She would like to make sure pharmacies know that the brand Imitrex nasal and injection are going to be preferred, so they have time to stock their shelves.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

SKELETAL MUSCLE RELAXANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CYCLOBENZAPRINE (ORAL)	64.3%	ON	Yes-Generic			
CHLORZOXAZONE (ORAL)	0.6%	ON	Yes-Generic			
TIZANIDINE TABLETS (ORAL)	12.8%	ON	Yes-Generic			
METHOCARBAMOL (ORAL)	6.1%	ON	Yes-Generic			
CARISOPRODOL (ORAL)	2.1%	OFF	No-Generic			
BACLOFEN (ORAL)	12.8%	ON	Yes-Generic			
CARISOPRODOL COMPOUND (ORAL)	0.0%	OFF	No-Generic			
ORPHENADRINE (ORAL)	0.2%	OFF	No-Generic			
LORZONE (ORAL)	0.0%	OFF	No			
ORPHENADRINE COMPOUND (ORAL)	0.0%	OFF	No-Generic			
DANTROLENE SODIUM (ORAL)	0.4%	ON	Yes-Generic			
CARISOPRODOL 250 MG (ORAL)	0.1%	OFF	No			
SOMA 250 MG (ORAL)	0.0%	OFF	No			
METAXALONE (ORAL)	0.5%	OFF	No			
ZANAFLEX CAPSULE (ORAL)	0.0%	OFF	No			
FEXMID (ORAL)	0.0%	OFF	No-Generic			
AMRIX (ORAL)	0.0%	OFF	No			
CYCLOBENZAPRINE ER (ORAL)	0.1%	OFF	No-Generic			
TIZANIDINE CAPSULES (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Kevin Iazard
 - All members were in favor of this motion.
 - Motion passes

BLADDER RELAXANT PREPARATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OXYBUTYNIN TABLET (ORAL)	38.4%	ON	Yes-Generic			
OXYBUTYNIN SYRUP (ORAL)	2.0%	ON	Yes-Generic			
OXYTROL (TRANSDERM.)	0.4%	OFF	No			
SANCTURA XR (ORAL)	0.6%	OFF	No			
VESICARE (ORAL)	41.0%	ON	Yes			
TOVIAZ (ORAL)	5.0%	ON	Yes			
ENABLEX (ORAL)	2.7%	OFF	No			
DETROL (ORAL)	0.5%	OFF	No			
GELNIQUE (TRANSDERM.)	0.3%	OFF	No			
DETROL LA (ORAL)	4.1%	OFF	No			
OXYBUTYNIN ER (ORAL)	4.8%	OFF	No-Generic			
TROSPIUM (ORAL)	0.3%	OFF	No-Generic			
SANCTURA (ORAL)	0.0%	OFF	No			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

BONE RESORPTION SUPPRESSION AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MIACALCIN (NASAL)	4.1%	ON	Yes			
ALENDRONATE TABLETS (ORAL)	86.5%	ON	Yes-Generic			
FORTICAL (NASAL)	0.1%	OFF	No			
BONIVA (ORAL)	2.2%	OFF	No			
ACTONEL (ORAL)	2.4%	OFF	No			
FOSAMAX PLUS D (ORAL)	0.3%	OFF	No			
FOSAMAX SOLUTION (ORAL)	0.0%	OFF	No			
EVISTA (ORAL)	3.7%	OFF	No			
ATELVIA (ORAL)	0.1%	OFF	No			
CALCITONIN SALMON (NASAL)	0.5%	OFF	No-Generic			
DIDRONEL (ORAL)	0.0%	OFF	No			
ETIDRONATE DISODIUM (ORAL)	0.0%	OFF	No-Generic			

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

COLONY STIMULATING FACTORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LEUKINE (INJECTION)	1.9%	OFF	No			
NEUPOGEN DISP SYRIN (INJECTION)	40.6%	ON	Yes			
NEUPOGEN VIAL (INJECTION)	36.8%	ON	Yes			
NEULASTA (INJECTION)	20.8%	OFF	No			

Discussion: None

- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second- Alicia Walker
 - All members were in favor of this motion.
 - Motion passes

ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPOGEN (INJECTION)	0.0%	OFF	No			
ARANESP DISP SYRIN (INJECTION)	4.0%	ON	Yes			
ARANESP VIAL (INJECTION)	23.4%	ON	Yes			
PROCRIT (INJECTION)	72.5%	ON	Yes			

Discussion: None

- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - All members were in favor of this motion.
 - Motion passes

GROWTH HORMONE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OMNITROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
SAIZEN VIAL (INJECTION)	0.0%	OFF	Yes			
SAIZEN CARTRIDGE (INJECTION)	0.0%	OFF	Yes			
TEV-TROPIN VIAL (INJECTION)	0.0%	OFF	No			
NUTROPIN AQ CARTRIDGE (INJECTION)	11.7%	ON	Yes			
SEROSTIM VIAL (INJECTION)	0.0%	OFF	No			
NUTROPIN AQ VIAL (INJECTION)	0.8%	ON	Yes			
NUTROPIN VIAL (INJECTION)	0.8%	ON	Yes			
NORDITROPIN PEN (INJECTION)	52.5%	ON	Yes			
GENOTROPIN CARTRIDGE (INJECTION)	17.5%	ON	No			
HUMATROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
GENOTROPIN DISP SYRIN (INJECTION)	16.8%	ON	No			
OMNITROPE VIAL (INJECTION)	0.0%	OFF	No			
HUMATROPE VIAL (INJECTION)	0.0%	OFF	No			
ZORBTIVE VIAL (INJECTION)	0.0%	OFF	No			

Discussion:

- Kevin Izard and James Boblin questioned if the only difference between the various growth hormone products are the delivery device. How does Saizen work? Is it difficult to teach members how to use these products? What are the differences in storage requirements for these products?
- Rick Pope stated the Saizen comes in a cartridge and works very similar to the others and the only difference is the device that the drug comes in. Rick Pope also stated that it should be easy to teach members how to use a particular device.
- Rachel Currans-Henry stated members with a specific barrier to learning a new device would be able to indicate this for consideration on renewal PA requests for non-preferred products.
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second- Rosanne Barber
 - The vote was 7 to 2 in favor of the motion. Al Liegel and James Boblin oppose.
 - Motion passes

ADRODROGENIC AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANDRODERM (TRANSDERM)	19.9%	ON	Yes			
TESTIM (TRANSDERM.)	1.2%	OFF	Yes			
ANDROGEL GEL PUMP (TRANSDERM)	31.8%	ON	Yes			
ANDROGEL GEL PACKET (TRANSDERM.)	47.0%	ON	Yes			
FORTESTA (TRANSDERM)	0.0%	OFF	No			
AXIRON (TRANSDERM)	0.1%	OFF	No			

Discussion: None

- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Michael Witkovsky
 - The vote was 8 to 1 in favor of the motion. Alicia Walker opposed.
 - Motion passes

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOXAZOSIN (ORAL)	15.9%	ON	Yes-Generic			
TERAZOSIN (ORAL)	8.4%	ON	Yes-Generic			
TAMSULOSIN (ORAL)	53.0%	ON	Yes-Generic			
FINASTERIDE (ORAL)	20.5%	ON	Yes-Generic			
CARDURA XL (ORAL)	0.0%	OFF	No			

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RAPAFLO (ORAL)	0.1%	OFF	No			
AVODART (ORAL)	1.7%	OFF	No			
JALYN (ORAL)	0.2%	OFF	No			
ALFUZOSIN (ORAL)	0.3%	OFF	No-Generic			

Discussion: None

- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

PHOSPHATE BINDERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PHOSLYRA (ORAL)	0.8%	OFF	No			
ELIPHOS (ORAL)	0.0%	ON	Yes-Generic			
CALCIUM ACETATE CAPSULE (ORAL)	41.7%	ON	Yes-Generic			
CALCIUM ACETATE TABLET (ORAL)	0.1%	OFF	No			
FOSRENOL (ORAL)	6.2%	ON	Yes			
RENAGEL (ORAL)	43.7%	ON	Yes			
REVELA TABLET (ORAL)	6.5%	OFF	No			
REVELA POWDER PACK (ORAL)	1.0%	OFF	No			

Discussion: None

- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

OPIATE DEPENDENCE TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BUPRENORPHINE HCL (SUBLINGUAL)	7.3%	ON	Yes-Generic			
SUBOXONE FILM (SUBLINGUAL)	91.3%	ON	Yes			
SUBOXONE TABLETS (SUBLINGUAL)	1.3%	ON	Yes	OFF	OFF	

Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented but have the Suboxone tablets as non-preferred.
 - Second- James Boblin
 - All members were in favor of this motion.
 - Motion passes